MedTrace Logo

A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

NCT04911751 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-01-07

No results posted yet for this study

Summary

The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.

Conditions

  • Psoriatic Plaque

Interventions

DRUG

KBL697

1 capsule BID of KBL697 or Placebo

DRUG

KBL697

5 capsules BID of KBL697 or Placebo

Sponsors & Collaborators

  • KoBioLabs

    lead INDUSTRY

Principal Investigators

  • Ira Thorla · Louisiana Dermatology Associates

  • Jose Cardona · Indago Research and Health Center

  • Jennifer Soung · Southern California Dermatology, Inc

  • James Krell · Total Skin and Beauty Dermatology Center

  • Paul Yamauchi · Clinical Science Institute

  • Ivette Espinosa-Fernandez · Revival Research Institute

  • Annika Smith · Westmead Hospital

  • Deirdre Murrell · Premier Specialist

  • Lynda Spelman · Veracity Clinical Trials Ltd

  • Samantha Eisman · Sinclair Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-08
Primary Completion
2023-11-08
Completion
2024-10-07
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04911751 on ClinicalTrials.gov